Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02542046 · ClinicalTrials.gov registry record

Uniformity of Oral Contrast Material in the Bowel

A clinical trial, sponsored by University of California, San Francisco.

Completed
Registry status
900
Enrollment target

NCT02542046 is a clinical trial that has completed, run by University of California, San Francisco. The registered enrollment target is 900 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02542046 has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
900 participants
Enrollment target

Study Summary

Although positive oral contrast agents are used for the majority of abdominopelvic CT scans in the United States, the quality of bowel opacification has not been compared between the three major classes of positive oral contrast material (barium sulfate, ionic iodinated contrast material, and non-ionic iodinate contrast material). This is a retrospective single institution study of clinical records to show whether the uniformity of bowel opacification is different between the three main types of positive CT oral contrast material used in the United States (Barium sulfate, Diatrizoate, and Iohexol). The investigators will retrospectively identify 250 patients each who received oral barium sulfate, diatrizoate, and iohexol for CT scanning of the abdomen and pelvis (total 750 patients) and assess the quality of bowel lumen opacification by the positive oral contrast agents.

Interventions

  • DRUG Iohexol
  • DRUG Barium
  • DRUG Diatrizoate

Trial Details

FieldValue
Enrollment Target 900 participants
Start Date 2015-09
Est. Completion 2018-01

What the Registry Record Tells You About NCT02542046

The ClinicalTrials.gov registry entry for NCT02542046 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Iohexol is the first listed.

NCT02542046 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02542046 about?

NCT02542046 is a clinical study titled "Uniformity of Oral Contrast Material in the Bowel". Although positive oral contrast agents are used for the majority of abdominopelvic CT scans in the United States, the quality of bowel opacification has not been compared between the three major classes of positive oral contrast material (barium sulfate, ionic iodinated contrast material, and non-io...

What is the current status of trial NCT02542046?

This trial is currently completed. The enrollment target is 900 participants. The study started on 2015-09. Estimated completion is 2018-01.

What interventions are being tested in trial NCT02542046?

The interventions under investigation include: Iohexol (DRUG), Barium (DRUG), Diatrizoate (DRUG).

Who is sponsoring clinical trial NCT02542046?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.